COVID-19 Vaccine and Bariatric Surgery for Hypertension

COVID-19 Vaccine

Happy Monday. We’re hoping that your week is off to a good start. We’re pleased to have good news to report this week. First, Phase I and II trials of a COVID-19 vaccine show promising results. Also, patients who are mildly obese and taking hypertension medications may benefit from bariatric surgery

COVID-19 Vaccine Presents Minimum Adverse Events

An analysis of two randomized clinical trials of a COVID-19 vaccine in China showed promising results, a report in JAMA shows. In the phase I trial, 96 healthy adults were either given aluminum hydroxide or a low, medium, and high doses of a COVID-19 vaccine. In the phase II trial, 224 adults received a medium dose of the vaccine on either day 0 and 14 or day 0 and 28. Both control groups took to aluminum hydroxide.

The most significant adverse events occurred in up to 25% of patients by day seven of the phase I trial. These events were mainly a mild fever and pain of the injection site. Overall, the researchers concluded that the groups experienced low adverse events. More importantly, the vaccine groups did experience immunity. Before making any conclusions, phase III trials must happen to ensure the vaccine is genuinely safe and effective. 

Bariatric Surgery May Reduce Medication Needs for Patients with Hypertension

For patients who are obese and also have hypertension, bariatric surgery may both reduce their weight and decrease the amount of medication they need to take. A new study published in the Annals of Internal Medicine looked at 100 moderately obese individuals with hypertension who were all taking at least two medications. 

The participants — who are from Sao Paulo Brazil — either received weight-loss counseling with the surgery or weight loss counseling without surgery. Both groups received treatment for hypertension. After their respective treatments, the patient’s blood pressure medication use, blood pressure levels, and other laboratory markers were monitored for three years. 

On average, the surgery group reduced the number of medications they were on to just one. Also, 35% of the surgery group were medication-free with controlled blood pressure. Currently, bariatric surgery in patients who are mildly obese isn’t recommended, but this trial’s outcome could set a new standard. That said, this was a single-center nonblind trial, so not the gold standard of research. More research is needed before surgery for a new population becomes the norm. 

Andrew Gutman

Andrew Gutman

Andrew Gutman is the Managing Editor of MedShadow and a former Senior Associate Editor for Muscle & Fitness. He writes about exercise and nutrition for Business Insider, Insider Health, Gear Patrol, and Men's Health.

Did you find this article helpful?

Leave a Reply

Your email address will not be published. Required fields are marked *

Latest News

No Link Found Between H1N1 Vaccine and Autism

No Link Found Between H1N1 Vaccine and Autism

In the quest to discover the causes for Autism Spectrum Disorder (ASD), influenza (H1N1) vaccine can be taken off the chopping block. A recent study out of Sweden, and published in the Annals of Internal Medicine, reported no link between mother’s receiving the H1N1 vaccine while pregnant and their babies…

Diet as Effective as Bariatric Surgery for Managing Blood Sugar (And a lot Safer)

Diet as Effective as Bariatric Surgery for Managing Blood Sugar (And a lot Safer)

For those with Type-2 diabetes, bariatric surgery has been shown by certain studies to have therapeutic effects on metabolic function independent of just weight loss. However, a new study in the New England Journal of Medicine has shown that it is indeed weight loss ls which yields the most dramatic…

  • Advertisement